Prospera Financial Services Inc Invests $123,000 in Illumina, Inc. (NASDAQ:ILMN)

Prospera Financial Services Inc purchased a new position in Illumina, Inc. (NASDAQ:ILMNGet Rating) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 352 shares of the life sciences company’s stock, valued at approximately $123,000.

A number of other hedge funds have also recently made changes to their positions in the stock. D.A. Davidson & CO. grew its holdings in Illumina by 153.2% during the 4th quarter. D.A. Davidson & CO. now owns 1,904 shares of the life sciences company’s stock worth $724,000 after acquiring an additional 1,152 shares in the last quarter. CWM LLC bought a new position in Illumina during the 4th quarter worth about $423,000. Assenagon Asset Management S.A. grew its holdings in Illumina by 8.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,207 shares of the life sciences company’s stock worth $840,000 after acquiring an additional 179 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Illumina by 1.4% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 44,646 shares of the life sciences company’s stock worth $16,985,000 after acquiring an additional 632 shares in the last quarter. Finally, TFC Financial Management grew its holdings in Illumina by 35.8% during the 4th quarter. TFC Financial Management now owns 417 shares of the life sciences company’s stock worth $159,000 after acquiring an additional 110 shares in the last quarter. 86.62% of the stock is currently owned by institutional investors.

Illumina Price Performance

Illumina stock opened at $223.77 on Friday. The company’s fifty day moving average price is $204.20 and its 200 day moving average price is $279.28. Illumina, Inc. has a 1 year low of $173.45 and a 1 year high of $526.00. The stock has a market capitalization of $35.15 billion, a P/E ratio of 48.65, a P/E/G ratio of 1.75 and a beta of 1.15. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.54 and a current ratio of 1.85.

Illumina (NASDAQ:ILMNGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The life sciences company reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.20. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.22 billion. Illumina had a return on equity of 8.37% and a net margin of 15.04%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.89 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on ILMN shares. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and dropped their target price for the stock from $350.00 to $150.00 in a report on Wednesday, July 13th. Citigroup decreased their price target on shares of Illumina from $325.00 to $220.00 and set a “neutral” rating for the company in a research report on Friday, July 8th. Cowen decreased their price target on shares of Illumina from $506.00 to $492.00 in a research report on Friday, May 6th. Canaccord Genuity Group decreased their price target on shares of Illumina from $555.00 to $520.00 and set a “buy” rating for the company in a research report on Friday, May 6th. Finally, Piper Sandler decreased their price target on shares of Illumina from $460.00 to $360.00 and set a “na” rating for the company in a research report on Sunday, May 15th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $398.67.

Insider Buying and Selling at Illumina

In other Illumina news, SVP Alexander Aravanis sold 539 shares of the firm’s stock in a transaction on Thursday, July 7th. The stock was sold at an average price of $200.00, for a total value of $107,800.00. Following the transaction, the senior vice president now owns 3,346 shares in the company, valued at approximately $669,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Illumina news, SVP Alexander Aravanis sold 539 shares of the firm’s stock in a transaction on Thursday, July 7th. The stock was sold at an average price of $200.00, for a total value of $107,800.00. Following the transaction, the senior vice president now owns 3,346 shares in the company, valued at approximately $669,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Susan H. Tousi sold 250 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $214.85, for a total value of $53,712.50. Following the completion of the transaction, the senior vice president now owns 41,833 shares in the company, valued at approximately $8,987,820.05. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by insiders.

Illumina Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Articles

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNGet Rating).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.